The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gemcitabine (CAS 95058-81-4) Market Research Report 2024
Synopsis
Gemcitabine (CAS 95058-81-4), C9H11F2N3O4, the formula weight is 263.2, and its form is white to yellow powder.
Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.
The global Gemcitabine (CAS 95058-81-4) market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Gemcitabine (CAS 95058-81-4) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Gemcitabine (CAS 95058-81-4) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Gemcitabine (CAS 95058-81-4) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
1g/Vial
200mg/Vial
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma
Gemcitabine (CAS 95058-81-4), C9H11F2N3O4, the formula weight is 263.2, and its form is white to yellow powder.
Gemcitabine is used as a second-line treatment for patients with advanced pancreatic cancer after fluorouracil failure, and can improve the quality of life of patients. Secondly, it is a first-line application for locally advanced (stage III) and already metastatic (stage IV) non-small cell lung cancer.
The global Gemcitabine (CAS 95058-81-4) market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Gemcitabine (CAS 95058-81-4) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Gemcitabine (CAS 95058-81-4) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Gemcitabine (CAS 95058-81-4) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
1g/Vial
200mg/Vial
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Lilly France
Hansoh Pharma
Hisun Pharma
Pude Pharma
Qilu Pharma
Jari Pharma
HPGC
Yibantian Pharma
Actavis
Accord Healthcare
Mylan
Novartis
Salius Pharma
Index1 Gemcitabine (CAS 95058-81-4) Market Overview
1.1 Product Overview and Scope of Gemcitabine (CAS 95058-81-4)
1.2 Gemcitabine (CAS 95058-81-4) Segment by Type
1.2.1 Global Gemcitabine (CAS 95058-81-4) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 1g/Vial
1.2.3 200mg/Vial
1.3 Gemcitabine (CAS 95058-81-4) Segment by Application
1.3.1 Gemcitabine (CAS 95058-81-4) Sales Comparison by Application: (2021-2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Gemcitabine (CAS 95058-81-4) Market Size Estimates and Forecasts
1.4.1 Global Gemcitabine (CAS 95058-81-4) Revenue 2016-2027
1.4.2 Global Gemcitabine (CAS 95058-81-4) Sales 2016-2027
1.4.3 Gemcitabine (CAS 95058-81-4) Market Size by Region: 2016 Versus 2021 Versus 2027
2 Gemcitabine (CAS 95058-81-4) Market Competition by Manufacturers
2.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Manufacturers (2016-2021)
2.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Gemcitabine (CAS 95058-81-4) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Gemcitabine (CAS 95058-81-4) Manufacturing Sites, Area Served, Product Type
2.5 Gemcitabine (CAS 95058-81-4) Market Competitive Situation and Trends
2.5.1 Gemcitabine (CAS 95058-81-4) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Gemcitabine (CAS 95058-81-4) Players Market Share by Revenue
2.5.3 Global Gemcitabine (CAS 95058-81-4) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gemcitabine (CAS 95058-81-4) Retrospective Market Scenario by Region
3.1 Global Gemcitabine (CAS 95058-81-4) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Gemcitabine (CAS 95058-81-4) Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Gemcitabine (CAS 95058-81-4) Market Facts & Figures by Country
3.3.1 North America Gemcitabine (CAS 95058-81-4) Sales by Country
3.3.2 North America Gemcitabine (CAS 95058-81-4) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Gemcitabine (CAS 95058-81-4) Market Facts & Figures by Country
3.4.1 Europe Gemcitabine (CAS 95058-81-4) Sales by Country
3.4.2 Europe Gemcitabine (CAS 95058-81-4) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Gemcitabine (CAS 95058-81-4) Market Facts & Figures by Region
3.5.1 Asia Pacific Gemcitabine (CAS 95058-81-4) Sales by Region
3.5.2 Asia Pacific Gemcitabine (CAS 95058-81-4) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Gemcitabine (CAS 95058-81-4) Market Facts & Figures by Country
3.6.1 Latin America Gemcitabine (CAS 95058-81-4) Sales by Country
3.6.2 Latin America Gemcitabine (CAS 95058-81-4) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Gemcitabine (CAS 95058-81-4) Market Facts & Figures by Country
3.7.1 Middle East and Africa Gemcitabine (CAS 95058-81-4) Sales by Country
3.7.2 Middle East and Africa Gemcitabine (CAS 95058-81-4) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Gemcitabine (CAS 95058-81-4) Historic Market Analysis by Type
4.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2016-2021)
4.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Type (2016-2021)
4.3 Global Gemcitabine (CAS 95058-81-4) Price by Type (2016-2021)
5 Global Gemcitabine (CAS 95058-81-4) Historic Market Analysis by Application
5.1 Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2016-2021)
5.2 Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Application (2016-2021)
5.3 Global Gemcitabine (CAS 95058-81-4) Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Lilly France
6.1.1 Lilly France Corporation Information
6.1.2 Lilly France Description and Business Overview
6.1.3 Lilly France Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Lilly France Product Portfolio
6.1.5 Lilly France Recent Developments/Updates
6.2 Hansoh Pharma
6.2.1 Hansoh Pharma Corporation Information
6.2.2 Hansoh Pharma Description and Business Overview
6.2.3 Hansoh Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Hansoh Pharma Product Portfolio
6.2.5 Hansoh Pharma Recent Developments/Updates
6.3 Hisun Pharma
6.3.1 Hisun Pharma Corporation Information
6.3.2 Hisun Pharma Description and Business Overview
6.3.3 Hisun Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Hisun Pharma Product Portfolio
6.3.5 Hisun Pharma Recent Developments/Updates
6.4 Pude Pharma
6.4.1 Pude Pharma Corporation Information
6.4.2 Pude Pharma Description and Business Overview
6.4.3 Pude Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Pude Pharma Product Portfolio
6.4.5 Pude Pharma Recent Developments/Updates
6.5 Qilu Pharma
6.5.1 Qilu Pharma Corporation Information
6.5.2 Qilu Pharma Description and Business Overview
6.5.3 Qilu Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Qilu Pharma Product Portfolio
6.5.5 Qilu Pharma Recent Developments/Updates
6.6 Jari Pharma
6.6.1 Jari Pharma Corporation Information
6.6.2 Jari Pharma Description and Business Overview
6.6.3 Jari Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Jari Pharma Product Portfolio
6.6.5 Jari Pharma Recent Developments/Updates
6.7 HPGC
6.6.1 HPGC Corporation Information
6.6.2 HPGC Description and Business Overview
6.6.3 HPGC Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 HPGC Product Portfolio
6.7.5 HPGC Recent Developments/Updates
6.8 Yibantian Pharma
6.8.1 Yibantian Pharma Corporation Information
6.8.2 Yibantian Pharma Description and Business Overview
6.8.3 Yibantian Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Yibantian Pharma Product Portfolio
6.8.5 Yibantian Pharma Recent Developments/Updates
6.9 Actavis
6.9.1 Actavis Corporation Information
6.9.2 Actavis Description and Business Overview
6.9.3 Actavis Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Actavis Product Portfolio
6.9.5 Actavis Recent Developments/Updates
6.10 Accord Healthcare
6.10.1 Accord Healthcare Corporation Information
6.10.2 Accord Healthcare Description and Business Overview
6.10.3 Accord Healthcare Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Accord Healthcare Product Portfolio
6.10.5 Accord Healthcare Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Gemcitabine (CAS 95058-81-4) Description and Business Overview
6.11.3 Mylan Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Mylan Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Corporation Information
6.12.2 Novartis Gemcitabine (CAS 95058-81-4) Description and Business Overview
6.12.3 Novartis Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Novartis Product Portfolio
6.12.5 Novartis Recent Developments/Updates
6.13 Salius Pharma
6.13.1 Salius Pharma Corporation Information
6.13.2 Salius Pharma Gemcitabine (CAS 95058-81-4) Description and Business Overview
6.13.3 Salius Pharma Gemcitabine (CAS 95058-81-4) Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Salius Pharma Product Portfolio
6.13.5 Salius Pharma Recent Developments/Updates
7 Gemcitabine (CAS 95058-81-4) Manufacturing Cost Analysis
7.1 Gemcitabine (CAS 95058-81-4) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Gemcitabine (CAS 95058-81-4)
7.4 Gemcitabine (CAS 95058-81-4) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Gemcitabine (CAS 95058-81-4) Distributors List
8.3 Gemcitabine (CAS 95058-81-4) Customers
9 Gemcitabine (CAS 95058-81-4) Market Dynamics
9.1 Gemcitabine (CAS 95058-81-4) Industry Trends
9.2 Gemcitabine (CAS 95058-81-4) Growth Drivers
9.3 Gemcitabine (CAS 95058-81-4) Market Challenges
9.4 Gemcitabine (CAS 95058-81-4) Market Restraints
10 Global Market Forecast
10.1 Gemcitabine (CAS 95058-81-4) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Gemcitabine (CAS 95058-81-4) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Gemcitabine (CAS 95058-81-4) by Type (2022-2027)
10.2 Gemcitabine (CAS 95058-81-4) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Gemcitabine (CAS 95058-81-4) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Gemcitabine (CAS 95058-81-4) by Application (2022-2027)
10.3 Gemcitabine (CAS 95058-81-4) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Gemcitabine (CAS 95058-81-4) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Gemcitabine (CAS 95058-81-4) by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) Comparison by Application (2021-2027)
Table 3. Global Gemcitabine (CAS 95058-81-4) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Gemcitabine (CAS 95058-81-4) Covered in This Study
Table 5. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) of Key Manufacturers (2016-2021)
Table 6. Global Gemcitabine (CAS 95058-81-4) Sales Share by Manufacturers (2016-2021)
Table 7. Global Gemcitabine (CAS 95058-81-4) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Gemcitabine (CAS 95058-81-4) Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Gemcitabine (CAS 95058-81-4) Manufacturing Sites and Area Served
Table 11. Manufacturers Gemcitabine (CAS 95058-81-4) Product Type
Table 12. Global Gemcitabine (CAS 95058-81-4) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Gemcitabine (CAS 95058-81-4) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gemcitabine (CAS 95058-81-4) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Gemcitabine (CAS 95058-81-4) Sales by Region (2016-2021) & (Kg)
Table 16. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Region (2016-2021)
Table 17. Global Gemcitabine (CAS 95058-81-4) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Gemcitabine (CAS 95058-81-4) Sales by Country (2016-2021) & (Kg)
Table 19. North America Gemcitabine (CAS 95058-81-4) Sales Market Share by Country (2016-2021)
Table 20. North America Gemcitabine (CAS 95058-81-4) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Gemcitabine (CAS 95058-81-4) Revenue Market Share by Country (2016-2021)
Table 22. Europe Gemcitabine (CAS 95058-81-4) Sales by Country (2016-2021) & (Kg)
Table 23. Europe Gemcitabine (CAS 95058-81-4) Sales Market Share by Country (2016-2021)
Table 24. Europe Gemcitabine (CAS 95058-81-4) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Gemcitabine (CAS 95058-81-4) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Gemcitabine (CAS 95058-81-4) Sales by Region (2016-2021) & (Kg)
Table 27. Asia Pacific Gemcitabine (CAS 95058-81-4) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Gemcitabine (CAS 95058-81-4) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region (2016-2021)
Table 30. Latin America Gemcitabine (CAS 95058-81-4) Sales by Country (2016-2021) & (Kg)
Table 31. Latin America Gemcitabine (CAS 95058-81-4) Sales Market Share by Country (2016-2021)
Table 32. Latin America Gemcitabine (CAS 95058-81-4) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Gemcitabine (CAS 95058-81-4) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Gemcitabine (CAS 95058-81-4) Sales by Country (2016-2021) & (Kg)
Table 35. Middle East and Africa Gemcitabine (CAS 95058-81-4) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Gemcitabine (CAS 95058-81-4) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Gemcitabine (CAS 95058-81-4) Revenue Market Share by Country (2016-2021)
Table 38. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Type (2016-2021)
Table 39. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Type (2016-2021)
Table 40. Global Gemcitabine (CAS 95058-81-4) Revenue (Million US$) by Type (2016-2021)
Table 41. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Type (2016-2021)
Table 42. Global Gemcitabine (CAS 95058-81-4) Price (USD/Kg) by Type (2016-2021)
Table 43. Global Gemcitabine (CAS 95058-81-4) Sales (Kg) by Application (2016-2021)
Table 44. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Application (2016-2021)
Table 45. Global Gemcitabine (CAS 95058-81-4) Revenue (Million US$) by Application (2016-2021)
Table 46. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Application (2016-2021)
Table 47. Global Gemcitabine (CAS 95058-81-4) Price (USD/Kg) by Application (2016-2021)
Table 48. Lilly France Corporation Information
Table 49. Lilly France Description and Business Overview
Table 50. Lilly France Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. Lilly France Gemcitabine (CAS 95058-81-4) Product
Table 52. Lilly France Recent Developments/Updates
Table 53. Hansoh Pharma Corporation Information
Table 54. Hansoh Pharma Description and Business Overview
Table 55. Hansoh Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. Hansoh Pharma Gemcitabine (CAS 95058-81-4) Product
Table 57. Hansoh Pharma Recent Developments/Updates
Table 58. Hisun Pharma Corporation Information
Table 59. Hisun Pharma Description and Business Overview
Table 60. Hisun Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Hisun Pharma Gemcitabine (CAS 95058-81-4) Product
Table 62. Hisun Pharma Recent Developments/Updates
Table 63. Pude Pharma Corporation Information
Table 64. Pude Pharma Description and Business Overview
Table 65. Pude Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. Pude Pharma Gemcitabine (CAS 95058-81-4) Product
Table 67. Pude Pharma Recent Developments/Updates
Table 68. Qilu Pharma Corporation Information
Table 69. Qilu Pharma Description and Business Overview
Table 70. Qilu Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. Qilu Pharma Gemcitabine (CAS 95058-81-4) Product
Table 72. Qilu Pharma Recent Developments/Updates
Table 73. Jari Pharma Corporation Information
Table 74. Jari Pharma Description and Business Overview
Table 75. Jari Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. Jari Pharma Gemcitabine (CAS 95058-81-4) Product
Table 77. Jari Pharma Recent Developments/Updates
Table 78. HPGC Corporation Information
Table 79. HPGC Description and Business Overview
Table 80. HPGC Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. HPGC Gemcitabine (CAS 95058-81-4) Product
Table 82. HPGC Recent Developments/Updates
Table 83. Yibantian Pharma Corporation Information
Table 84. Yibantian Pharma Description and Business Overview
Table 85. Yibantian Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 86. Yibantian Pharma Gemcitabine (CAS 95058-81-4) Product
Table 87. Yibantian Pharma Recent Developments/Updates
Table 88. Actavis Corporation Information
Table 89. Actavis Description and Business Overview
Table 90. Actavis Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 91. Actavis Gemcitabine (CAS 95058-81-4) Product
Table 92. Actavis Recent Developments/Updates
Table 93. Accord Healthcare Corporation Information
Table 94. Accord Healthcare Description and Business Overview
Table 95. Accord Healthcare Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 96. Accord Healthcare Gemcitabine (CAS 95058-81-4) Product
Table 97. Accord Healthcare Recent Developments/Updates
Table 98. Mylan Corporation Information
Table 99. Mylan Description and Business Overview
Table 100. Mylan Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 101. Mylan Gemcitabine (CAS 95058-81-4) Product
Table 102. Mylan Recent Developments/Updates
Table 103. Novartis Corporation Information
Table 104. Novartis Description and Business Overview
Table 105. Novartis Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 106. Novartis Gemcitabine (CAS 95058-81-4) Product
Table 107. Novartis Recent Developments/Updates
Table 108. Salius Pharma Corporation Information
Table 109. Salius Pharma Description and Business Overview
Table 110. Salius Pharma Gemcitabine (CAS 95058-81-4) Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 111. Salius Pharma Gemcitabine (CAS 95058-81-4) Product
Table 112. Salius Pharma Recent Developments/Updates
Table 113. Production Base and Market Concentration Rate of Raw Material
Table 114. Key Suppliers of Raw Materials
Table 115. Gemcitabine (CAS 95058-81-4) Distributors List
Table 116. Gemcitabine (CAS 95058-81-4) Customers List
Table 117. Gemcitabine (CAS 95058-81-4) Market Trends
Table 118. Gemcitabine (CAS 95058-81-4) Growth Drivers
Table 119. Gemcitabine (CAS 95058-81-4) Market Restraints
Table 120. Global Gemcitabine (CAS 95058-81-4) Sales Forecast by Type (2022-2027) & (Kg)
Table 121. Global Gemcitabine (CAS 95058-81-4) Sales Market Share Forecast by Type (2022-2027)
Table 122. Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 123. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share Forecast by Type (2022-2027)
Table 124. Global Gemcitabine (CAS 95058-81-4) Sales Forecast by Application (2022-2027) & (Kg)
Table 125. Global Gemcitabine (CAS 95058-81-4) Sales Market Share Forecast by Application (2022-2027)
Table 126. Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 127. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share Forecast by Application (2022-2027)
Table 128. Global Gemcitabine (CAS 95058-81-4) Sales Forecast by Region (2022-2027) & (Kg)
Table 129. Global Gemcitabine (CAS 95058-81-4) Sales Market Share Forecast by Region (2022-2027)
Table 130. Global Gemcitabine (CAS 95058-81-4) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 131. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share Forecast by Region (2022-2027)
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Gemcitabine (CAS 95058-81-4)
Figure 2. Global Gemcitabine (CAS 95058-81-4) Market Share by Type in 2020 & 2027
Figure 3. 1g/Vial Product Picture
Figure 4. 200mg/Vial Product Picture
Figure 5. Global Gemcitabine (CAS 95058-81-4) Market Share by Application in 2020 & 2027
Figure 6. Hospital Pharmacies
Figure 7. Retail Pharmacies
Figure 8. Online Pharmacies
Figure 9. Global Gemcitabine (CAS 95058-81-4) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Gemcitabine (CAS 95058-81-4) Market Size 2016-2027 (US$ Million)
Figure 11. Global Gemcitabine (CAS 95058-81-4) Sales 2016-2027 (Kg)
Figure 12. Global Gemcitabine (CAS 95058-81-4) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 13. Gemcitabine (CAS 95058-81-4) Sales Share by Manufacturers in 2020
Figure 14. Global Gemcitabine (CAS 95058-81-4) Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Gemcitabine (CAS 95058-81-4) Players: Market Share by Revenue in 2020
Figure 16. Gemcitabine (CAS 95058-81-4) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Region (2016-2021)
Figure 18. Global Gemcitabine (CAS 95058-81-4) Sales Market Share by Region in 2020
Figure 19. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region (2016-2021)
Figure 20. Global Gemcitabine (CAS 95058-81-4) Revenue Market Share by Region in 2020
Figure 21. U.S. Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Taiwan Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Philippines Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Vietnam Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. U.A.E Gemcitabine (CAS 95058-81-4) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Gemcitabine (CAS 95058-81-4) by Type (2016-2021)
Figure 46. Sales Market Share of Gemcitabine (CAS 95058-81-4) by Application (2016-2021)
Figure 47. Sales Market Share of Gemcitabine (CAS 95058-81-4) by Application in 2020
Figure 48. Revenue Share of Gemcitabine (CAS 95058-81-4) by Application (2016-2021)
Figure 49. Revenue Share of Gemcitabine (CAS 95058-81-4) by Application in 2020
Figure 50. Manufacturing Cost Structure of Gemcitabine (CAS 95058-81-4)
Figure 51. Manufacturing Process Analysis of Gemcitabine (CAS 95058-81-4)
Figure 52. Gemcitabine (CAS 95058-81-4) Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
